Bioinductive Collagen Graft for Rotator Cuff Tears
Trial Summary
What is the purpose of this trial?
The rotator cuff is a complex of 4 tendons that aid in stabilizing and moving the shoulder. Rotator cuff tears are common shoulder injuries in adults. While some tears can be managed by physiotherapy, other rotator cuff tears will require surgery. On occasion, when a person has had a large rotator cuff tear for a long period of time, the tear can grow and the tendons retract. This effect makes it very difficult for the tendons to be repaired to their normal spot. The most common surgical technique employed to manage a tear that cannot be repaired is to remove all unhealthy, inflamed scar tissue in a process called debridement. Often there is a bone spur that must be shaved down as well. This can help to reduce the pain in the patient as well as assist the range of motion slightly but will not prevent the tear becoming larger. This will also not prevent a re-tear of the tendons. Recently, surgeons have begun using a variety of materials to help reconstruct torn rotator cuffs. New grafts made of highly purified collagen from bovine tendons has been used to bridge large gaps in the tendons, and repair the tendon back to the bone. This technique has been done many times by skilled shoulder surgeons in Canada, the United States and around the world. Initial reports by surgeons who do this procedure show that the patients have less pain and better range of motion than before the surgery. Shoulder surgeons do not know which is the better treatment for large rotator cuff tears. Both treatments (graft and debridement) can reduce pain and improve movement of the shoulder. The purpose of this study is to help determine whether patients who receive an allograft have better function and fewer re-tear at one year after surgery than those who received a debridement alone.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Regeneten for rotator cuff tears?
Is the Bioinductive Collagen Graft safe for treating rotator cuff tears?
How is the Regeneten treatment different from other treatments for rotator cuff tears?
The Regeneten treatment is unique because it uses a bio-inductive collagen implant to encourage new tissue growth and increase tendon thickness, which can help improve healing in rotator cuff repairs. This approach is different from traditional methods that may not address the issue of poor tissue quality in the rotator cuff.12346
Research Team
Ivan Wong, MD
Principal Investigator
Orthopaedic Surgeon
Eligibility Criteria
Adults over 18 with MRI-confirmed large rotator cuff tears (>3cm) are eligible for this trial. It's not suitable for those with shoulder cancer, arthritis, certain types of tear and osteoarthritis, high WORC scores, uncontrolled diabetes (Hgb A1C >7%), infections, comprehension issues post-surgery, nonvascular surgical sites, poor nutrition (Alb <30 g/L), inability to consent, pregnancy or shoulder paralysis/contracture.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either a regular rotator cuff repair with debridement or a graft-augmented repair with a bioinductive collagen implant
Early Recovery
Participants recover from surgery and initial outcomes such as pain and shoulder function are assessed
Follow-up
Participants are monitored for healing, re-tear rates, and overall shoulder function
Treatment Details
Interventions
- Regeneten
Regeneten is already approved in United States, Canada for the following indications:
- Rotator cuff tears
- Partial-thickness rotator cuff tears
- Full-thickness rotator cuff tears
- Rotator cuff tears
- Partial-thickness rotator cuff tears
- Full-thickness rotator cuff tears
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ivan Wong
Lead Sponsor
Smith & Nephew, Inc.
Industry Sponsor
Dr. Maria Berkman
Smith & Nephew, Inc.
Chief Medical Officer since 2023
MD from Harvard Medical School
Dr. Deepak Nath
Smith & Nephew, Inc.
Chief Executive Officer since 2022
PhD in Theoretical Mechanics, University of California, Berkeley